Latest News in the pharma Industry

Research & Development

Enterprise Therapeutics secures £4M funding to advance therapies for patients with respiratory disease

Enterprise Therapeutics secures £4M funding to advance therapies for patients with respiratory disease

10 Nov 2016

Funding will allow the company to advance its research projects and move closer towards its goal of evaluating the efficacy of muco-regulatory drugs in patients.

Read more 
Allergan enters into licensing agreement with AstraZeneca to obtain worldwide rights to MEDI2070 inflammatory disorder development program

Allergan enters into licensing agreement with AstraZeneca to obtain worldwide rights to MEDI2070 inflammatory disorder development program

3 Oct 2016

MEDI2070 is in development as a next-generation IL-23-only targeted therapy for Crohn's disease and ulcerative colitis.

Read more 
Late-breaking data show Novartis' Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients

Late-breaking data show Novartis' Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients

2 Oct 2016

Cosentyx significantly superior to Stelara in delivering long-lasting skin clearance in psoriasis over 52 weeks.

Read more 
Researchers find a gap in the brain’s firewall against Parkinson’s disease

Researchers find a gap in the brain’s firewall against Parkinson’s disease

2 Oct 2016

NIH-funded mouse study identifies a key player in the progression of the disorder.

Read more 
Eppendorf to showcase solutions to common lab challenges at Lab Innovations 2016

Eppendorf to showcase solutions to common lab challenges at Lab Innovations 2016

28 Sep 2016

The company will exhibit and demonstrate a range of instruments and consumables from the liquid handling portfolio, including: pipettes & tips, manual and electronic dispensers and automated pipetting systems.

Read more 
Theratechnologies to move forward with development of new single vial formulation for Egrifta

Theratechnologies to move forward with development of new single vial formulation for Egrifta

28 Sep 2016

The introduction of a single vial presentation was part of commitments required by the FDA when it approved Egrifta (Tesamorelin for Injection).

Read more 
Biogen completes rolling submission of NDA to FDA for nusinersen as a treatment for spinal muscular atrophy

Biogen completes rolling submission of NDA to FDA for nusinersen as a treatment for spinal muscular atrophy

27 Sep 2016

Submission of Marketing Authorization Application to the EMA planned in the coming weeks.

Read more 
BARDA Grants $43.2 million USD to Sanofi Pasteur for Zika

BARDA Grants $43.2 million USD to Sanofi Pasteur for Zika

26 Sep 2016

Funds will be used for Phase II development and manufacturing.

Read more 
Novartis receives three new FDA approvals for the expanded use of Ilaris

Novartis receives three new FDA approvals for the expanded use of Ilaris

23 Sep 2016

Ilaris is the first and only US FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF disease.

Read more 
To produce biopharmaceuticals on demand, just add water

To produce biopharmaceuticals on demand, just add water

22 Sep 2016

Freeze-dried cellular components can be rehydrated to churn out useful proteins.

Read more 
Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs

Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs

22 Sep 2016

Results published in the New England Journal of Medicine demonstrate that KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites.

Read more 
EMA validates BMS’s type II variation application for Opdivo in advanced form of bladder cancer

EMA validates BMS’s type II variation application for Opdivo in advanced form of bladder cancer

20 Sep 2016

Extends the current indications for Opdivo to include the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.

Read more